Glioblastoma survival has not improved in the last 30 years and there is an urgent need to develop novel therapeutic approaches for it.

Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor ...

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor ...

Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations revealed findings from the preclinical evaluation of 1H5, a novel monoclonal antibody (mAb) candidate that inhibits ...

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

Used in conjunction with the oral sonosensitizing agent 5-ALA, the sonodynamic therapy led to a median OS of 15.7 months in ...

Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished ...